ZBH:NYSEZimmer Biomet Holdings, Inc. Analysis
Data as of 2026-03-11 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Zimmer Biomet (ZBH) is trading at $91.7, below its 20‑day ($96.8) and 50‑day ($92.2) moving averages, with a bearish MACD histogram and an RSI of 40.5, suggesting short‑term pressure around the $90.2 support level. Despite the technical weakness, the company delivered a Q4 earnings beat, posted 10.9% revenue growth, and announced a new share‑buyback alongside a $0.24 quarterly dividend, reinforcing confidence in cash flow and dividend sustainability. The DCF fair‑value of $113.7 and analyst median target of $100 imply an upside of roughly 9‑12%, while a forward PE of 10.2 versus a trailing PE of 25.8 highlights strong earnings acceleration expectations. With a low beta (0.35), moderate volatility (24% 30‑day), solid gross margins (≈70%) and a payout ratio of 27%, ZBH appears undervalued yet positioned for medium‑term upside.
Market Outlook
Short Term
< 1 yearKey Factors
- Recent earnings beat and buyback support near current price
- Technical downside pressure with MACD bearish and decreasing volume
- Proximity to $90.2 support level limiting downside risk
Medium Term
1–3 yearsKey Factors
- 10.9% revenue growth and forward PE of 10.2 indicating earnings acceleration
- DCF upside of ~12% and analyst median target above current price
- Sustainable dividend (27% payout) backed by strong operating cash flow
Long Term
> 3 yearsKey Factors
- Strategic digital and robotic product pipeline (ROSA, ZBEdge) driving future growth
- Low beta and solid cash generation supporting dividend stability
- Undervaluation relative to intrinsic value and industry peers
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.